A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies (NCT07154823)
🩺 Plain-English Summary (8th-Grade Level)
The TEMPUS AQUARIUS Study is a non-interventional, longitudinal observational study focused on hematological malignancies. It will collect rich molecular (multi-omic) and clinical data from patient cohorts through serial blood draws and the acquisition of leftover tissue and/or bone marrow aspirates during their routine therapy and disease monitoring. The primary goal is to understand the association between biomarkers and real-world clinical outcomes in these patient populations.
Who can join: Review the eligibility criteria below.
Location: University of Iowa Hospital and Clinics — Iowa City, Iowa
Age range: 0 Years
🧪 Interventions in This Study
- None - Observational Study (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (9 Sites)
- University of Iowa Hospital and Clinics — Iowa City, Iowa
- The Center for Cancer and Blood Disorders — Bethesda, Maryland
- Washington University in St. Louis — St Louis, Missouri
- Cancer Care Specialists of Reno — Reno, Nevada
- University of Cincinnati — Cincinnati, Ohio
- OhioHealth Research Institute — Columbus, Ohio
- Taylor Cancer Research Center — Maumee, Ohio
- Cancer Care Associates of York — York, Pennsylvania
- Avera Cancer Institue — Sioux Falls, South Dakota
📞 Contact the Study Coordinator
Phone: (800) 739-4137
Email: aquarius@tempus.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Acute Myeloid Leukaemia (AML)
- A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax — Boston, Massachusetts
- L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML — Birmingham, Alabama
Explore by condition: All Acute Myeloid Leukaemia (AML) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.